Circulating microRNA testing for the early diagnosis and follow-up of colorectal cancer patients

Molecular Diagnosis and Therapy

Volumn 18, Issue 3, 2014, Pages 303-308

  Fesler, Andrew ^a   Jiang, Jingting ^b   Zhai, Haiyan ^a   Ju, Jingfang ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TUMOR MARKER;

BODY FLUID; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; EARLY DIAGNOSIS; EXOSOME; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; PRIORITY JOURNAL; REVIEW; AGED; BLOOD; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR PATHOLOGY; PATHOLOGY;

AGED; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; EXOSOMES; FOLLOW-UP STUDIES; HUMANS; MICRORNAS; MIDDLE AGED; PATHOLOGY, MOLECULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 84902379524     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-014-0089-0     Document Type: Review

References (39)

1. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society; 2013. p. 1-64.
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-54. (Pubitemid 24014542)
3. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75(5):855-62 pii: 0092-86 74(93)90530-4.
4. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 2005;309(5740):1573-6. (Pubitemid 41266485)
5. Ruvkun G. Clarifications on miRNA and cancer. Science. 2006;311(5757):36-7.
6. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-9. doi:10.1073/pnas.242606799. (Pubitemid 35403967)
7. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007;13(10):1668-74. doi:10.1261/rna.642907. (Pubitemid 47481675)
8. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007;7:36. doi:10.1186/1472-6750-7-36.
9. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-8. doi:10.1073/pnas. 0804549105.
10. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285(23): 17442-52. doi:10.1074/jbc.M110.107821.
11. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-9. doi:10.1038/ncb1596. (Pubitemid 47214727)
12. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2012;5(3):492-7. doi:10.1158/1940-6207.CAPR-11-0370.
13. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010;38(20):7248-59. doi:10.1093/nar/gkq601.
14. Kim DJ, Linnstaedt S, Palma J, Park JC, Ntrivalas E, Kwak-Kim JY, et al. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagn. 2012;14(1): 71-80. doi:10.1016/j.jmoldx.2011.09.002.
15. Koberle V, Pleli T, Schmithals C, Augusto Alonso E, Haupenthal J, Bonig H, et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PloS ONE. 2013;8(9):e75184. doi:10.1371/journal.pone.0075184.
16. Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang L, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PloS ONE. 2012;7(9):e44398. doi:10.1371/journal.pone.0044398.
17. Yang IP, Tsai HL, Huang CW, Huang MY, Hou MF, Juo SH, et al. The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PloS One. 2013;8(6):e66842. doi:10.1371/journal.pone.0066842.
18. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2013. doi:10.1097/SLA.0b013e3182a6909d.
19. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138(10):1659-66. doi:10.1007/s00432-012-1244-9.
20. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127(1):118-26. doi:10.1002/ijc.25007.
21. Vega AB, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 2013;30(1):320-6. doi:10.3892/or.2013.2475.
22. Nugent M, Miller N, Kerin MJ. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol. 2012;106(8):947-52. doi:10.1002/jso.23174.
23. Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 2013;. doi:10.1016/j.molonc.2013.09.001.
24. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012;118(10):2603-14. doi:10.1002/cncr.26565.
25. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009;9(6):703-11. doi:10.1517/14712590902932889.
26. Leidner RS, Li L, Thompson CL. Dampening enthusiasm for circulating microRNA in breast cancer. PloS ONE. 2013;8(3): e57841. doi:10.1371/journal. pone.0057841.
27. Kanaan Z, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg. 2013;258(3):400-8. doi:10.1097/SLA.0b013e3182a15bcc.
28. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849-59. doi:10.1093/jnci/djt101.
29. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012;36(1):e61-7. doi:10.1016/j.canep.2011.05.002.
30. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patientswith colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58(10):1375-81. doi:10.1136/gut.2008.167817.
31. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25(10):1674-80. doi:10.1111/j.1440-1746.2010.06417.x.
32. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013;34(4):2175-81. doi:10.1007/s13277-013-0753-8.
33. Yong FL, Law CW, Wang CW. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer. 2013;13:280. doi:10.1186/1471-2407-13-280.
34. Yamada N, Nakagawa Y, Tsujimura N, Kumazaki M, Noguchi S, Mori T, et al. Role of intracellular and extracellular microRNA-92a in colorectal cancer. Transl Oncol. 2013;6(4):482-92.
35. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PloS ONE. 2011;6(3):e17745. doi:10.1371/journal.pone. 0017745.
36. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ Jr, et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 2009;69(20):8157-65. doi:10.1158/0008-5472.CAN-09-1996.
37. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther. 2009;8(5):1067-74. doi:10.1158/1535-7163.MCT-08-0592.
38. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72(5-6):397-402. doi:10.1159/000113489. (Pubitemid 351238155)
39. Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma MicroRNAs for early detection of colorectal cancer. PloS ONE. 2013;8(5):e62880. doi:10.1371/journal.pone.0062880.